ADC Therapeutics SA (ADCT) Fundamentals

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
SHARE INFORMATION
Market Cap$ 284,958,178
Shares Outstanding77,645,280
Float33,784,984
Percent Float43.51%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 33,917,000
Latest Fiscal EPS$ -3.00
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions107
Institutional Holdings Date2022-10-31
Institutional Bought Previous 3 Months1,191,638
Institutional Holdings Percent67.5%
Institutional Sold Previous 3 Months3,787,119
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned-
TRADING INFO
52 Week High$ 23.28
52 Week Low$ 3.60
52 Week High Change$ -83.42
21 Day Moving Average$ 4.1886
21 Day Extended Moving Average$ 4.1672
50 Day Moving Average$ 4.5764
50 Day Extended Moving Average$ 4.7788
200 Day Moving Average$ 8.7655
200 Day Extended Moving Average$ 9.2135
10 Day Average Volume841,637
20 Day Average Volume612,223
30 Day Average Volume481,125
50 Day Average Volume377,271
Alpha-0.066500
Beta1.1805
Standard Deviation0.176946
R20.130404
7 Day Price Change$ -0.64
7 Day Percent Change-14.85%
21 Day Price Change$ -0.46
21 Day Percent Change-11.14%
30 Day Price Change$ -1.11
30 Day Percent Change-23.22%
Month to Date Price Change$ -0.77
Month to Date Percent Change-17.34%
Quarter to Date Price Change$ -1.15
Quarter to Date Percent Change-23.86%
180 Day Price Change$ -3.84
180 Day Percent Change-51.13%
200 Day Price Change$ -7.28
200 Day Percent Change-66.48%
Year to Date Price Change$ -16.53
Year to Date Percent Change-81.83%

ADC Therapeutics SA (ADCT) Key Ratios

PROFITABILITY
EBIT Margin-96.7%
EBITDA Margin-95.1%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin96.9%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 157,120,000
Revenue Per Share$ 2.0236
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book3.20
Total Debt To Equity1.10
Int Coverage-3.90
Current Ratio5.00
Leverage Ratio4.10
Quick Ratio4.60
Long Term Debt To Capital0.50
VALUATION MEASURES
PE Ratio-1.70
Enterprise Value$ 26,190,347
Price to Sales1.8136
Price to Free Cash-1.90
PE High Last 5 Years0.00
Price To Book2.80
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book3.20
MANAGEMENT EFFECTIVENESS
Receivables Turnover7.40
Invoice Turnover0.40
Assets Turnover0.10
Return Assets-28.39
Return on Equity-113.68
Return on Capital-58.26

ADC Therapeutics SA (ADCT) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorPricewaterhouseCoopers AG
CEOChristopher Martin
Emplyoees312
Last AuditUE
CIK0001771910
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
AddressRoute de la Corniche 3B
Biopole
Epalinges, 1066
Websitehttps://www.adctherapeutics.com
Facsimile-
Telephone+41 216530200
Email-


Your Recent History
NYSE
ADCT
ADC Therap..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.